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Each patient has a unique history of cancer ecosystem development, resulting in intratumor heterogeneity. In order to effectively 
kill the tumor cells by chemotherapy, dynamic monitoring of driver molecular alterations is necessary to detect the markers for 
acquired drug resistance and find the new therapeutic targets. To perform the therapeutic monitoring, frequent tumor biopsy 
is needed, but it is not always possible due to small tumor size or its regression during the therapy or tumor inaccessibility in advanced 
cancer patients. Liquid biopsy appears to be a promising approach to overcome this problem, providing the testing of circulating 
tumor cells (CTC) and/or tumor-specific circulating nucleic acids. Their genomic characteristics make it possible to assess the 
clonal dynamics of tumors, comparing it with the clinical course and identification of driver mutation that confer resistance 
to therapy. The main attention in this review is paid to CTC. The biological behavior of the tumor is determined by specific cancer-
promoting molecular and genetic alterations of tumor cells, and by the peculiarities of their interactions with the microenvironment 
that can result in the presence of wide spectrum of circulating tumor clones with various properties and potentialities to contribute 
to tumor progression and response to chemotherapy and prognostic value. Indeed, data on prognostic or predictive value of CTC 
are rather contradictory, because there is still no standard method of CTC identification, represented by different populations 
manifesting various biological behavior as well as different potency to metastasis. Circulating clasters of CTC appear to have es-
sentially greater ability to metastasize in comparison with single CTC, as well as strong association with worse prognosis and 
chemoresistance in breast cancer patients. The Food and Drug Administration (USA) has approved the CTC-based prognostic test 
for clinical application in patients with advanced breast cancer. Prospective clinical trials have demonstrated that measuring 
changes in CTC numbers during treatment is useful for monitoring therapy response in breast cancer patients. Molecular and 
genetic analysis of CTC gives the opportunity to have timely information on emergence of resistant tumor clones and may shed light 
on the new targets for pathogenetic antitumor therapy.
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CLONAL EVOLUTION OF TUMORS 
PROVIDES INTRATUMOR HETEROGENEITY
The modern oncology paradigm was declared 
by Peter Nowell, who was the first to describe cancer 
as complex and branching evolutionary trajectories, 
in parallel with Darwin’s iconic evolutionary speciation 
tree. His concept was described in 1976 in his paper 
entitled “Clonal evolution of tumor cell population”, 
which was published in “Science” journal [1]. A classi-
cal or Darwinian evolutionary system embodies a basic 
principle: purposeless genetic variation of reproduc-
tive individuals, united by common descent, coupled 
with natural selection of the fittest variants [2].
Cancer is a process of a clonal evolution where 
sequential acquisition of mutations with concomi-
tant, successive subclonal dominance or selective 
sweeps results in the tumors with various molecular 
aberrations, thus requiring personalized approach 
to treatment. Intratumor clonal heterogeneity, mani-
festing as a coexistence of tumor cells with different 
genotypes and phenotypes within the same tumor, 
is considered to be an essential driving force providing 
tumor clonal evolution, progression, and resistance 
to chemo- and radiotherapy. The clonal heterogeneity 
of different primary tumor sites and differences in tu-
mor clones between primary tumors and metastases 
fail to provide a proper or accurate diagnosis as well 
as successful prognosis and treatment of cancer.
Breast cancer (BC) is the most common malignancy 
and is the leading cause of cancer-related mortality 
of women in developing countries [3]. The high BC mor-
tality is directly endowed by the failure in early detection 
of the disease and the lack of effective markers to esti-
mate the risk of cancer progression and to predict tumor 
response to chemotherapy and radiotherapy. Largely 
unsuccessful attempts to develop new approaches 
to prediction of response to therapy, and effective 
evaluation of the clinical course of BC can be mainly 
attributed to high intratumoral variety of this disease. 
Invasive carcinoma of no special type characterized 
by a significant intratumor morphological heterogeneity 
is the most common histological type of BC, accounting 
for approximately 80% of all cases. We determined the 
tubular structures as well as trabecular, solid, alveolar, 
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and discrete groups of tumor cells displaying archi-
tectural arrangement within the primary tumors [4, 5]. 
The morphological structure of the primary tumor was 
reported to be evidently related to clinical outcome, 
resulting from cancer progression clinically manifested 
as invasion, lymph node involvement, and distant 
metastases consistent with results obtained from 
analyzing the large cohorts of BC patients, the mor-
phological structure of the primary tumor was reported 
to be evidently related to clinical outcome, resulting 
from cancer progression clinically manifested as inva-
sion, lymph node involvement, and distant metastases. 
A contribution of intratumor morphological heteroge-
neity to chemotherapy efficiency was also shown [4, 
5]. High risk of lymphogenous metastasis was shown 
to be related with the presence of alveolar structures 
in tumors of postmenopausal women and with the 
increased number of different types of morphological 
structures in premenopausal women. The detection 
of alveolar structures and the greatest morphological 
diversity of breast tumors appeared to be associated 
with resistance to neoadjuvant chemotherapy [4–6].
In our study, the microarray transcriptional analysis 
of different morphological structures of breast tumors 
showed specific gene expression sets and non-coding 
sequences for each type of morphological structures 
as compared to normal breast epithelial cells. Con-
sistent with our data, different types of morphological 
structures in breast tumors belong to the functionally-
separated populations of tumor cells displaying ex-
pression of various specific genes. Essential variations 
in the expression pattern of signaling pathways endow-
ing tumor chemoresistance and contributing to tumor 
cell invasion of different structures were also shown 
(data are being prepared for publication).
Significant differences in the spectrum and func-
tional activity of the major cancer-related signaling 
pathways in different types of the above mentioned 
parenchymal structures corroborate their different 
contribution to tumor progression and serve as the 
basis for the identification of new prognosis markers 
and targets for therapeutic intervention.
Chemotherapy may destroy certain sensitive can-
cer clones and erode their habitats, but it can also 
provide a potent selective pressure for the expansion 
of resistant variants. Chemotherapy and radiotherapy 
induce the clonal evolution of tumor cell population, 
leading to the expansion of dominating drug resistant 
tumor clones, which are considered to be the major 
cause of tumor progression and anticancer treatment 
failures. Identification of the molecular mechanisms 
responsible for multidrug resistance could provide the 
opportunity for more effective control of tumor growth 
and progression [7].
Tumor clone evolution is forwarded through the 
interaction between tumor cells and microenviron-
ment as well as under the influence of genotoxic 
factors resulting in the occurrence of new mutations 
under conditions of high genetic instability. Tumors are 
composed of cells with driver changes and cell clones 
carrying neutral mutations, which are not selected, 
as well as a plurality of cells with random changes, 
which often may promote tumor growth. On the other 
hand, tumor cells can also dramatically influence to the 
microenvironment during evolution process, suppor-
ting tumor growth.
The primary driver mutations result in the activation 
of oncogenic signalling pathways and/or inactivation 
of tumor suppressors. They are important for tumor 
(carcinogenesis) and actually provide its biological 
behavior, determining the clinical course and outcome 
of the malignant process. The increased genetic insta-
bility in the primary malignant clone leads to the gene-
ration of new mutations (so-called secondary driver 
mutations) giving rise to new subclones, which may 
become dominant in the tumor over time. Passenger 
mutations are random single mutations that can both 
contribute to cancer progression and do not have any 
effect on the tumor behavior [8–11] (Fig. 1).
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Fig. 1. Different types of tumor clonal architecture. Tumor 
progression is presented as a growing tree. The distribution 
of primary (1) and secondary (2) driver mutations as well as pas-
senger mutations (3) within the tumor tree. Three types of tumor 
clonal architecture varying in the subclone amount were identi-
fied. The poor response likelihood depends on the type of tumor 
tree. Type “a” tumors contain more primary driver mutations 
and show good response to treatment. Other tumors (“c”) have 
a high genetic diversity, manifested in a greater representation 
of the secondary driver mutations and mutations “passengers”, 
and as a result, display poor therapeutic effect. Type “b” tumor 
response to therapy has intermediate value [10–12]
The dynamics of the somatic cell evolution is de-
pendent on the rate of mutation processes, genetic 
diversity and clonal expansion, and may be modified 
by such events as clonal interference (competition 
of clones having an advantage in the same adaptive 
environment) or parallel expansion with subsequent 
appearance of dominant clones [12–14]. The epige-
netic alterations, which are acquired more rapidly than 
genetic changes, contribute significantly to the clonal 
evolution. They can be inherited during cell division 
and may determine the tumor phenotype [15, 16]. 
Cancer tissue ecosystems provide the architectonic 
space and driving determinants for fitness selection, 
i.e. the so-called adaptive landscape [7, 17]. The tumor 
microenvironment is composed of multiple dynamically 
interacting components that can influence cancer clone 
evolution. For example, TGF-β, promoting dissemina-
tion of cancer cells through the induction of epithelial-
mesenchymal transition (EMT), is one of the critically 
important molecules regulating the tumor ecosystem, 
along with other inflammatory cytokines [12, 18].
The reciprocal interactions between tumor cells 
and the tumor microenvironment are regulated 
by both systemic factors (nutrients, hormones), and 
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mediators, which are produced by tumor-associated 
fibroblasts, endothelial cells, mesenchimal progeni-
tor cells or different types of infiltrating inflammatory 
cells and cancer cells itself. In each case, the exter-
nal environment, lifestyle, exposures to genotoxic 
agents, constitutive genetics of the host cells, sys-
temic regulators, local regulators (microenvironment) 
and architectural constraints provide the evolution 
of somatic cells, tumor biological behavior and out-
come [7].
Tumor cells can re-modulate the microenviron-
ment and create niches to endow their competitive 
advantage in growth and dissemination. The interac-
tion between tumor cells and the microenvironment 
can be dramatically modulated by chemotherapy 
or radiation therapy. Although the majority of cancer 
cells can be killed by cytotoxic agents, the landscape 
remodeling creates conditions for the selection and 
expansion of minor variants of tumor cells insensitive 
to treatment [19].
Thus, each patient has a unique history of the 
tumor development, and to have benefit from che-
motherapy, it is necessary to monitor molecular 
changes that can serve as both markers of acquired 
resistance and targets for the effects of other drugs. 
Chemotherapy, including targeted therapy, can 
be considered as the guiding factor in the cancer cell 
clone evolution, inducing the expansion of resistant 
clones instead of dead sensitive cells. For success-
ful treatment, it is necessary to know what a new 
driver clone has appeared during the chemotherapy 
to choose a proper drug for further therapy. For ex-
ample, patients with mutations in the tyrosine kinase 
domain of epidermal growth factor receptor (EGFR), 
whose tumors initially responded to chemotherapy 
with tyrosine kinase inhibitors (TKIs), would develop 
resistance to these TKIs. The acquired resistance 
to TKIs is provided by the appearance of additional 
mutations in the EGFR gene (particularly, T790M) [20] 
or in the chimeric gene ALK [21], altering the spatial 
structure of the coding protein, thereby abrogating 
its interaction with the inhibitor.
The identification of new driver mutations promotes 
the development of new drugs. For example, afatinib, 
a recently introduced new TKI, can be used for lung 
cancer patients. This inhibitor manifests its activity 
against T790M mutation occurring in 50% of patients 
who showed resistance during the treatment with 
EGFR-targeted TKIs gefitinib or erlotinib [22].
The development of drug resistance phenotype, 
contributing to insensitivity of tumor to chemotherapy 
in 80–90% of cases is one of the crucial mechanisms 
of cancer progression [23, 24].
To estimate chemoresistance of intratumor 
morphological heterogeneity of BC, we studied the 
expression levels of different genes, coding the ABC-
transporter family, in various parenchymal structures, 
such as alveolar, tubular, trabecular, solid structures 
and individual cells. We showed the different gene 
expression profiles in various structures and revealed 
that the activation of ABC gene expression occurred 
most frequently in the trabecular structures [25].
In our study we also directly showed the partial 
destruction of tumor clones during neoadjuvant 
chemotherapy for BC patients, using the detec-
tion of copy number variation (CNV) as a numerical 
chromosome aberration, namely deletions or ampli-
fications, in various loci. To study the CNV, microar-
ray analysis was performed using the high density 
microarray platform Affymetrix (USA), CytoScanTM 
HD Array [26, 27]. We tested CNV in breast tumor 
biopsy before treatment and in surgical specimens 
after preoperative chemotherapy. We observed par-
tial elimination of tumor clones carrying deletions 
and amplifications in a patient who had achieved 
clinical partial regression of the primary tumor after 
preoperative chemotherapy (Fig. 2). In the patient 
E, whose tumor progressed while recei ving chemo-
therapy, along with the disappearance of the clones, 
the emergence of new clones was observed, which 
appeared to provide drug resistance and tumor pro-
gression (metastasis to bones, soft tissues, lungs 
and cervical lymph nodes).
ba
Fig. 2. Change of tumor clones during the preoperative che-
motherapy in patients with BC. CNV of DNA (deletion or ampli-
fication of chromosomal regions and individual chromosomes) 
in breast tumor cells were determined. High density microarray 
(Affimetrix Cytoscan HD Array), which is able to detect the entire 
spectrum of mutant tumor clones was used. Red shows dele-
tions, blue — amplification. The genetic landscape of a tumor 
prior (a) to treatment and after (b) treatment [27]
The biological behavior of the tumor is determined 
by specific cancer-promoting molecular and genetic 
alterations of tumor cells, and by the peculiarities 
of their interactions with the microenvironment. There-
fore, the study of the properties of tumor cells is ne-
cessary to provide successful cancer care of patients, 
including diagnosis, choice of therapy, monitoring 
of the treatment efficacy, prognosis of disease course 
and prediction of therapy response.
Moreover, the molecular profiling of tumors and the 
development of the so-called precision oncology are 
becoming increasingly important in the management 
and therapy of cancer patients. A precision approach 
requires monitoring of the natural molecular evolution 
of individual tumors to develop the appropriate tar-
geted therapies for each patient [28]. The personalized 
medicine assumes the systemic use of patient-specific 
genetic information (both germline and somatic) and 
molecular or/and cellular tumor characteristics to se-
lect the optimal treatments with the goal of improved 
therapeutic efficacy and reduced toxicity [29–31]. The 
precision medicine is considered as a general trend 
in the development of targeted therapy.
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CIRCULATING TUMOR CELLS: DEFINITION 
AND DETECTION
In clinical practice, the objective obstacles exist 
to obtain a sufficient amount of tumor material that can 
be tested at different steps of examination and treat-
ment of cancer patients. The restrictions are caused 
by impossibility to perform multiple biopsies, lack 
of sufficient amount of tumor tissue or its complete 
disappearance on pathological examination in patients 
with complete pathological response. It is also impor-
tant that the material derived from a limited number 
of tumor sites, may not accurately reflect the tumor 
heterogeneity, because the different tumor sites may 
contain different cell clones with specific molecular 
characteristics and biological behavior. This can lead 
to diagnostic errors and misinterpretation of molecular 
testing results to prescribe specific targeted therapies.
The testing of tumor properties using circulating 
tumor cells (CTC) and/or circulating tumor-specific 
nucleic acids derived from blood-sample (“liquid bio-
psy”) is considered a promising alternative to analysis 
of tumor biopsy. Molecular characteristics of circulat-
ing tumor-specific DNA/RNA or CTC will enable the 
assessment of tumor clonal dynamics related to clini-
cal course and detection of driver genetic changes 
conferring resistance to therapy. In this review we fo-
cused on CTC that gave rise to the term “liquid biopsy”, 
proposed by the National Institute of Health (USA), 
as opposed to a standard tissue biopsy and later 
nucleic acids included in notion “liquid biopsy” [32].
However, it should be noted that the phenomenon 
of intratumoral heterogeneity resulted from the pro-
cess of tumor clonal evolution through the interaction 
between tumor cells and microenvironment as well 
as under the influence of chemotherapeutic agents 
may provide the failure of “liquid biopsy” for disease 
prognosis and prediction of chemotherapy response.
This is due to the presence of cell clones within 
a tumor with different functional properties providing 
diversity in their biological behavior responsible for 
clinical course of disease (metastasis) and sensitivity 
(resistance) to therapy. Therefore, one can expect 
the coexistence of wide spectrum of circulating tu-
mor clones with various properties and potentialities 
to contribute to tumor progression and response 
to chemotherapy. Considering the behavioral varia-
bility of distinct subpopulations of CTC in the blood 
we can assumed that they have different prognostic 
and predictive value.
In this review numerous experimental and clinical 
results were analyzed to show the diversity and vari-
ability in phenotype and genotype of CTC and their 
prognostic significance. Data on prognostic or predic-
tive value of CTC are rather contradictory, because 
there are still no standard appropriate methods of CTC 
identification, represented by different populations 
manifesting various biological behavior endowing 
different potency to metastasis.
Tumor cells in the bloodstream are detected after 
the tumor removal in 30% of patients with different 
malignancies, including BC. They are also detected 
in the bone marrow of 20–60% of BC patients (so-
called disseminated tumor cells — DTC). It is known 
that BC metastases may occur even 20 years after the 
treatment, and more than 30% of the patients without 
clinical evidence of the disease appeared to have CTC 
in the blood stream, indicating that tumor cells can 
survive in a state of dormancy for long periods [33].
Since it is known that the intravasation of tumor 
cells from primary tumor into the circulation is a obliga-
tory prerequisite for metastasis [34], it is quite obvi-
ous that the presence of CTC may reflect the risk 
of metastatic disease in a particular patient. There 
are many published studies evaluating the prognostic 
significance of CTC as a factor of high risk for meta-
stasis [35, 36]. However, there are also other studies 
that have not shown that CTCs are able to predict the 
risk of cancer dissemination [37, 38].
There are the following reasons for these contro-
versial results: lack of a standard method of identifi-
cation of CTC, lack of fundamental knowledge of the 
phenotypic and genetic characteristics of different 
CTC populations, mechanisms of metastasis, and the 
absence of validated information about their relation 
with the clinical course of the disease.
Along with single CTC, the circulating clusters 
or micrometastases (2–50 united cell) have been 
found in the blood of patients with various malignan-
cies [39]. CTC clasters, which are responsible for the 
development of future metastases, are a result of the 
collective invasion and subsequent intravasation of tu-
mor cells into lymphatic or blood vessels. It is assumed 
that their penetration into the blood vessels occurs 
in the areas of destruction of the endothelium [40], 
and is promoted by tumor cells undergoing EMT [41] 
as well as by cooperation with tumor-associated fi-
broblasts [42], eventually contributing to proteolysis 
of the vascular walls. Vascular endothelial growth 
factor has been shown to contribute to the collective 
cell intravasation into blood stream and accumulation 
of tumor clusters [43].
A recent study using a mouse model of BC has 
shown that CTC clusters have oligoclonal origin from 
primary tumor cell groups, thus confirming the fact 
of intravasation and denying the opportunity of a ran-
dom aggregation of clusters from single CTC [44]. 
Along with the mechanism of cluster origin by invasion 
of cell groups to the blood vessels, there are published 
data on circulating clusters organized from single 
proliferated cancer stem cell adhered to the endothe-
lium [45], or by the aggregation of single cancer stem 
cell with blood cells, in particular with lymphocytes 
and platelets. A recent study confirmed that CTC are 
composed of tumor cells, although some cases (< 5%) 
demonstrated the presence of immune system cells 
expressing CD45, CD68, CD14 and other markers 
in their structure. All CTC showed a low expression 
of transcripts encoding epithelial CTC markers, such 
as keratin, mucin 1 (MUC1), epithelial cell adhesion 
molecule (EpCAM) and/or CDH1 [46, 47].
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Numerous CTC detection techniques have been 
developed so far. The cytological CTC identification 
method was first proposed by Nabar in 1959. However, 
this method was found to be low in specificity. The most 
commonly used CTC detection approach is based 
on the use of monoclonal antibodies against epithe-
lial markers, such as EpCAM and cytokeratin (CK), 
provided that CTC do not express hematopoietic cell 
markers. The Cellsearch System™ ® (Veridex, Warren, 
NJ, USA), the first Food and Drug Administration-
approved commercial automated system developed 
for the identification of EpCAM+, CKs 8, 18, 19+, CD45− 
and nuclear cells, is considered as an effective tool for 
determining prognosis in patients with metastatic BC, 
prostate cancer and colorectal cancer [48].
Considering the fact that the CTC detection using 
different markers can identify cell subpopulations 
with different biological behavior, it is obvious that 
the Cellsearch system has significant limitations be-
cause it detects the epithelial markers only. However, 
it is known that EpCAM expression is downregulated 
during EMT, and gain of mesenchymal markers such 
as vimentin and fibronectin was found to correlate with 
a worse prognosis more effectively than CK-positive 
cells [49]. Recent studies show that CTC markers may 
change over the course of therapy [50].
AdnaTestBreast™ test is based on the CTC detec-
tion by assessing the EpCAM gene expression [37]. 
However, a prospective German multicenter trial 
(DETECT) showed no correlation between CTC and 
disease-free or overall survival [37].
The microfluidic platform (the “CTC-chip”) deals 
with small blood volumes and uses antibodies against 
the common epithelial cell surface marker EpCAM [51]. 
Recently, a refined methodology called “herringbone-
chip”, or “HB-Chip”, has been developed to provide 
an enhanced platform for CTC isolation. The CTC chip 
was created for isolation of rare CTC in patients with 
breast, lung and prostate cancers [52].
The immunospot assay (Elispot) method is also used 
for detection of CTC or bone marrow DTC. Using this 
method, only viable tumor cells are detected and appro-
priate cytokine secretion is studied at the individual cell 
level. The reverse transcription quantitative polymerase 
chain reaction (PCR), is used for detecting of CTC 
marker gene expression, such as CK-19, mucin 1, mam-
moglobin, EGFR and CK-20. In the metastatic BC set-
ting, plasma levels of the miR-200 family, as well as a few 
other circulating microRNAs, are highly correlated with 
CTC in the blood and show great potential in predicting 
the survival of these patients [53].
CTC isolated from blood by different methods can 
be assessed by immunohistochemistry for specific 
markers. Fluorescence in situ hybridization is used 
to detect gene amplification or translocations. DNA 
or RNA extracted from the CTC can be used for the 
reverse transcription quantitative PCR to assay gene 
expression profiling. However, the isolation of CTC 
with high purity as well as the getting alive cells 
to be cultivated in vitro is a technical problem. All 
these approaches focus on the detection of already 
known molecular changes, whereas the full genome 
sequencing can be used for the detection of new aber-
rations, and the expression profiling for the detection 
of previously unknown activated signaling pathways 
providing CTC function.
Thus, it is obvious that the efficiency of using CTC 
as markers depends on the detection method, as dif-
ferent types of CTC with different metastatic potential 
can be identified. Different technologies may detect 
different CTC subpopulation with different sensitivity 
and purity.
PROPERTIES AND PHENOTYPE 
OF CIRCULATING TUMOR CELLS
The common definition of CTC designate them 
as epithelial cells with characteristics of the primary 
tumor cells, which are able to initiate the metastasis, 
and therefore, they can be regarded as a marker 
for prediction of distant metastases [53]. However, 
it is only partially true, because in order to leave the 
primary tumor, cancer cells must acquire certain 
properties, namely: locomotor phenotype due to EMT, 
ability to survive in the bloodstream, avoiding anoikis 
(cell death induced by the loss of attachment to the 
epithelial cell layer), resistance to chemotherapy and 
immune-mediated death in the bloodstream. For this, 
the clonogenic potential and ability to return to the 
epithelial phenotype (mesenchymal-epithelial transi-
tion) are important conditions for providing tumor cell 
homing to secondary organs and formation of mac-
rometastasis [53].
CTC are extremely rare, estimated as one CTC per 
billion normal blood cells in the circulation of patients 
with advanced cancer. They can passively enter the 
blood circulation during vessel damage or surgery, 
as well as via an active migration process, mov-
ing away from the primary tumor and entering the 
blood circulation due to their conversion to the EMT 
phenotype. The level of epithelial E-cadherin expres-
sion decreases, while the level of neural N-cadherin 
expression increases, thus resulting in the violation 
of cell adhesion. At the same time, the extracellular 
matrix is destroyed by matrix metalloproteinases and 
components of the urokinase plasminogen activator 
system. Increased expression of EMT markers has 
been found in the CTC and bone marrow disseminated 
cells. Depending on the origin of the primary tumor, 
CTC have different properties and different surface 
markers: epithelial cell markers, such as EpCAM, CK+, 
EMT-related genes such as vimentin, fibronectin, etc., 
and stem cell markers, such as CD44+ CD24− ALDH+ 
(aldehydedehydrogenase). CTC can also express 
different molecules of major cell signaling pathways, 
such as EGFR, PI3K, Akt, etc. [54]. It is important 
to note that CTC can also colonize their primary tu-
mors, accelerating cancer progression [55].
The activation of WNT signaling pathway involved 
in the regulation of cell adhesion was found in 30% 
of CTC in contrast to only 1% of WNT activated cells 
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found in the primary tumor [44]. The WNT pathway 
is known to provide inhibition of tumor cell death via 
anoikis, that results in their survival in bloodstream.
The co-expression of EMT markers TWIST and stem 
cell markers ALDH1 on circulating pan-cytokeratin 
positive cells was found in 30% of early BC patients 
and in 80% of metastatic BC patients. In a recent study, 
Schindlbeck et al. compared CTC enumeration with 
DTC detection using CellSearch technology in patients 
with primary or metastatic BC [56]. The authors found 
a significant concordance (69.4%) between DTC and 
CTC, which increased in patients with metastases. 
Other authors identified EMT markers, such as PI3Kα, 
Akt-2, and TWIST1, and stem cell markers, such 
as ALDH1, Bmi1 and CD44 in CTCs of patients with 
early BC [57].
As for circulating clusters, they were characterized 
by the increased levels of tissue inhibitor of matrix 
metalloprotease-1 (TIMP1) and platelet transcripts, 
and were in a hybrid state of EMT when the expres-
sion of both epithelial and mesenchymal transition 
took place [58, 59]. This state of EMT was reported 
to be chara cteristic of collective invasion and was as-
sociated with more aggressive cancer [59, 60].
Another study identified the adhesion molecule 
plakoglobin, as being higher expression in circula-
ting cell cluster than in single CTC [44]. Cheung et al. 
reported that CTC clusters and lung metastases fre-
quently expressed epithelial cytoskeletal protein, kera-
tin 14 (K14). The RNA sequencing analysis revealed 
that K14 positive cells were enriched for desmosome 
and hemidesmosome adhesion complex gene, and 
were depleted for MHC class II genes. Suppression 
of K14 expression resulted in the inhibition of distant 
metastases, likely, through a violation of the acti vity 
of numerous molecular players, including tenas-
cin C (Tnc), Jagged 1 protein (Jag 1) and epiregulin 
(Ereg) [39].
CIRCULATING TUMOR CELLS: RELATION 
TO METASTASIS AND THERAPY 
RESPONSE
Evaluation of the prognostic significance of CTC 
in patients with early BC is intensively carried out. 
There are many reports indicating that the pre-
sence of CTC is associated with lower overall and 
progression-free survival rates [61, 62]. The authors 
argue that EMT-associated markers in CTC predict 
unfavorable prognosis more effectively than epithelial 
markers [49]. It indicates more aggressive metastatic 
potential of cells carrying EMT markers due to the high 
potential for extravasation and subsequent adaptation 
in the microenvironment at secondary sites, namely 
premetastatic niches.
The properties of tumor cells, providing their meta-
static potential, are significantly modified under the 
influence of microenvironment, including endothelial 
cells, fibroblasts, inflammatory cells (macrophages, 
neutrophils), and mesenchymal stem cells [63]. Tu-
mor-associated macrophages enhance the invasive-
ness of the primary tumor cells, producing epidermal 
growth factors. Blood platelets aggregate with tumor 
cells, protecting them from damage in the blood-
stream. This likely explains the association between 
thrombocytosis and lower survival rates, and the ef-
fective use of anticoagulants to reduce the incidence 
of metastasis [63].
Cristofanilli et al. [64] in their study with a large co-
hort of BC patients concluded that the number of CTC 
was an independent predictor of progression-free sur-
vival as well as overall survival. The level of CTC of less 
than 5 tumor cells per 7.5 ml of blood was associated 
with high rates of disease-free and overall survival, but 
not with tumor response to chemotherapy [64].
As it was mentioned above, a validated test for CTC 
detection has been approved for clinical use in patients 
with metastatic BC. Numerous studies report that the 
detection rate of CTC is significantly higher in patients 
with disseminated BC than in patients with early BC 
(50–80% vs 5–13%) [56]. Thus, it can be concluded 
that the count of CTC with metastatic potential is higher 
in patients with advanced stages than in patients with 
early stages. The sensitivity of CTC detection tech-
niques can be reduced due to the low frequency of CTC 
in patients with early BC [65].
Krishnamurthy et al. [36] found no relationship 
between the frequency of CTC detection in patients 
with locally advancer BC and the standard prognostic 
factors, including hormone receptors and HER2/neu 
status. Circular tumor cells are believed can indepen-
dently predict dissemination to different secondary 
sites. The detection of CTC and DTC is considered 
as useful in selecting patients for adjuvant chemo-
therapy [36].
Rack et al. [66] evaluated 1767 BC patients for the 
presence of CTC and found the correlation between 
the CTC level and positive lymph nodes. Lang et al. [67] 
showed the correlation between CTC detection and 
bone marrow micrometastases and HER2 status of the 
primary tumor.
The tumors belonging to distinct molecular 
subtypes are known to have different responses 
to treatment and different clinical courses. Igna-
tiadis et al. [68] showed a prognostic significance 
of CK19 mRNA-positive CTC in patients with estrogen 
receptor-negative, triple-negative and HER2-positive 
BC. The authors reported elimination of CK 19 mRNA+ 
CTC during the treatment with trastuzumab, a hu-
manized anti-HER2 monoclonal antibody. The iden-
tification of CTC after adjuvant chemotherapy could 
serve as an independent predictor of tumor progres-
sion [68]. It was shown that in patients with metastatic 
BC, the treatment with lapatinib significantly reduced 
the number of HER2-positive CTC regardless of the 
HER2 status of the primary tumor. This finding gives 
the opportunity to monitor molecular changes during 
the target therapy to control its efficacy [69].
The c-erbB2 (HER2) gene amplification was shown 
to play a critical role in the pathogenesis of human 
BC. The activation of c-erbB2 gene was observed 
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in 20–30% of early BC. It was also demonstrated 
that HER2-positive CTC had a high metastatic po-
tential [33]. The heterogeneity of HER2 status was 
revealed, some tumor cells had HER2/neu gene 
amplification and others show normal copy numbers. 
It is interesting to note that HER2-positive CTC were 
found in 89% of HER2 negative patients, and these pa-
tients had a survival benefit after trastuzumab-based 
therapy [70]. The CTC test may provide the additional 
information for determining HER2 status of the tumor 
and administering trastuzumab [71].
The CTC monitoring during trastuzumab treat-
ment allows prediction of resistance to this drug and 
gives the opportunity of using appropriate inhibitors 
affecting STAT3 or PI3K/mTOR signaling pathways 
contributing to cancer progression. A series of studies 
were conducted to evaluate the response to therapy 
in BC patients with heterogeneity of HER2/neu ex-
pression in cells of the primary tumor and in CTC [33, 
70–73].
By studying the relationship between CTC with 
HER2 amplification and efficiency of targeted therapy, 
it can be assumed that it is crucial to determine the 
grade of heterogeneity of the targets for specific 
therapy, which influence the treatment outcome. For 
this, large-scale clinical trials are required.
Prospective studies provided data on the efficacy 
of CTC detection for monitoring chemotherapy [61, 
62]. Molecular studies of CTC might discover new 
molecular targets for treatment and predictors of poor 
response due to the emergence of resistant clones 
giving the opportunity to choose the drug. Molecular 
characterization of CTC may contribute to the develop-
ment of novel anticancer drugs.
In the SUCCESS (Simultaneous Study of Gem-
citabine-Docetaxel Combination Adjuvant Treatment, 
as well as Extended Bisphosphonate and Surveillance) 
trial, including 2026 patients with stage I–III BC, the 
CTC count detected before treatment using the Cell-
Search technology was an independent predictor 
of disease-free, overall and BC-specific survivals. 
CTC were tested during chemotherapy in 1492 pa-
tients and were detected in 22% of these patients. 
The median follow-up was 36 months. Recurrence 
was found in 28% of patients who had at least 5 CTC 
in the blood before the start of systemic treatment and 
in 7% of patients who had no CTC. A total of 14% of the 
CTC-positive patients died of BC compared with 3% 
of the CTC-negative patients. The presence of CTC 
both before the start of systemic adjuvant treatment 
and after completion of chemotherapy was associated 
with deteriorated survival [66].
It is known that CTC-clusters have a stronger abi-
lity to induce metastasis than the equivalent number 
of single CTC. This fact was reported in the early 70-ies 
of the last century, when CTC-clusters and single 
CTC were injected to the experimental animals and 
the number of metastatic foci were compared [74]. 
A recent study confirmed that CTC clusters indicated 
a metastatic potential 23 to 50 times greater than 
single CTC, and metastases developing from clusters 
led to dramatically reduced survival [48].
In mouse models of BC, experimentally aggre-
gating tumor cells into clusters displayed a >15-fold 
increase in colony formation ex vivo and a >100-fold 
increase in metastasis formation in vivo [39]. In this 
study, the authors observed CTC-clusters at different 
stages of metastasis, including collective invasion, 
local dissemination, intravasation, circulation and 
formation of micrometastases, and they demonstrated 
that the polyclonal dissemination of CTC-clusters 
is a frequent mechanism in a common mouse model 
of BC, accounting for more than 90% of all metas-
tases [39]. The recent studies demonstrate that the 
monitoring of CTC in combination with CTC-clusters 
provides a higher prognostic value in assessing the 
risk of metastatic spread of advanced BC compared 
to CTC detection alone [75].
There are also reports that CTC-clusters show 
higher resistance to chemotherapy than single 
CTC [47, 76]. The increased metastatic potential 
of CTC-clusters and their resistance to chemotherapy 
are likely to relate with the lack of proliferating cells and 
the ability of cells to avoid anoikis [76, 77]. In addition, 
an enhanced survival advantage of CTC clusters also 
might be afforded by continued production of auto-
crine pro-migratory factors, matrix proteases and 
protection of cells from immunological surveillance 
by lymphocytes and natural-killer cells.
Several studies have shown a significant portion 
of tumor cells involving in EMT within the cluster 
cell population, thus also explaining their resistance 
to chemotherapy [46, 77]. It is related to the increased 
activity of ABC transporters in EMT-cells, which are 
responsible for drug resistance. There are also reports 
that CTC clusters contain cells with a cancer stem cell 
phenotype, characterized by high metastatic poten-
tial [78].
The potential of CTC to predict relapse and overall 
survival in early BC patients may depend on timing 
of blood sampling, duration of follow-up and more 
importantly on the method of CTC detection. The dif-
ferent results obtained by different authors may be due 
to a number of objective reasons: the nature and pro-
perties of CTC in each individual patient are not known; 
CTC may shift from an active state to a dormant state, 
being resistant to chemotherapy and immune attack; 
there is no clear evidence whether chemotherapy 
results in the increase or decrease of CTC number.
It is particularly important that the conditions for the 
development of macrometastases are objectively va-
ried in different individuals. According to fundamental 
knowledge about the biology of tumor dissemination, 
the metastasis development is determined not only 
by the tumor cell behavior, but also the environment 
influencing their mobility, migration from the primary 
tumor and survival in the bloodstream and distant 
sites. Indeed, the Paget’s “seed and soil” hypothesis 
(1889) was proposed to explain that metastasis is a re-
sult of cross-talk between selected cancer cells (the 
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“seeds”) and specific organ microenvironments (the 
“soil”) [79]. This idea was later developed by Lyden 
into the concept of “metastatic niches” [80]. Primary 
tumor cells provide tumor invasion and regulate cre-
ation of pre-metastatic niches by secreting various 
cytokines and growth factors, which promote the re-
lease of cells from the tumor and mobilization of bone 
marrow cells into metastatic niches [81].
It is known that in patients with certain types of tu-
mors, for example, with luminal subtype of BC, meta-
stases can occur many years after initial diagnosis 
[38]. This is due to the phenomenon of “dormant 
tumor”, when tumor cells extravasated in the secon-
dary sites (pre-metastatic niches) do not proliferate 
and do not form macrometastases.
Initiation of secondary tumor growth is induced 
by the specific conditions related to various types 
of injury (trauma, surgery, radiotherapy, chemo-
therapy), other stress, and inflammatory processes 
that are associated with the activation of regeneration 
processes [82, 83].
The presence of tumor cells in the circulation and 
metastatic sites is assumed not to be a sufficient con-
dition for macrometastasis, because even if CTC are 
present, the conditions of “soil” may not be fully taken 
into account. However, it should be noted that the un-
derestimation of the effect of “soil” does not detract 
from the value of CTC detection, as “side effect” in this 
case will always be a benefit for the patient’s survival, 
if there are no objective conditions for the development 
of macrometastases.
CONCLUSION
The numerous reports may justify the prospect 
of using the CTC detection not only in metastatic 
cancer, but also in the early stages of BC, thus im-
proving efficiency of the treatment for early BC. The 
fundamental knowledge about the nature of CTC, 
their properties, and the correlation between CTC and 
clinical course of disease indicate their high potential 
value as markers of tumor progression and targets for 
therapeutic intervention. High phenotypic and func-
tional heterogeneity of CTC open the opportunity for 
determining the molecular profile of different CTC sub-
populations to identify metastasis-related prognostic 
phenotype and genotype, providing the evaluation 
of metastatic potential.
Detection of molecular changes in CTCs during 
chemotherapy, resulted in chemoresistance, is the 
promising way to shift the course of chemotherapy 
right time as well as to find new therapeutic targets. 
The identification of CTC activated signaling pathways, 
contributing to clinical outcome, can provide an ef-
fective search for new drug targets. For example, the 
activation of WNT signaling pathway observed in 30% 
of CTC vs 1% of primary tumor cells provides inhibition 
of anoikis, showing the potential to identify the targets 
for pathogenetic therapy.
CTC are increasingly recognized as the main 
source for recurrence and metastasis. The develop-
ment of novel therapeutic techniques that target CTC 
includes:
•	dialysis after surgery to remove CTCs from the 
bloodstrem [84];
•	drugs that target cancer stem cells;
•	targeted drugs for various subclones of CTC;
•	identification and inactivation of signaling pathways 
that allow CTC to survive in the bloodstream and 
home to secondary sites.
Thus, we can conclude that further large-scale 
evidence-based clinical trials are needed to determine 
the prognostic and predictive value of CTC in BC, ta-
king into consideration the “price/benefit” ratio.
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